Circadian‑Timed Senolytic Therapy: Synchronizing Dasatinib+Quercetin Administration with REV-ERBα Troughs to Maximize Senescent Cell Clearance

Hypothesis

Administering the senolytic combination Dasatinib+Quercetin (D+Q) at the circadian phase when REV-ERBα expression is at its lowest (approximately CT6 in mice) will synergistically increase apoptotic clearance of senescent cells compared with constant or mistimed dosing, because senescent cells retain a dampened but still oscillatory clock that gates BCL‑2 family protein levels.

Mechanistic Rationale

• Senescent cells exhibit prolonged circadian periods and reduced amplitude of core clock genes, yet residual rhythmicity persists in regulators of apoptosis such as BCL-2, BCL-xL, and MCL-1, which are known to be transcriptionally repressed by REV-ERBα[1][2]
• REV-ERBα directly binds to RORE elements in the promoters of BCL-2 and BCL-xL, suppressing their transcription[3]
• In healthy tissues, REV-ERBα peaks during the subjective night, creating a trough of anti‑apoptotic BCL‑2 proteins at CT6; senescent cells, despite clock dampening, retain this phase relationship, creating a temporal window of heightened sensitivity to BCL‑2‑targeting senolytics.
• Dasatinib inhibits SRC family kinases that phosphorylate and stabilize BCL‑xL, while quercetin downregulates BCL‑2 via ERK pathway modulation; their combined effect is therefore maximal when baseline BCL‑2/BCL‑xL levels are lowest.

Experimental Design

1. Animal model: 20‑month‑old C57BL/6J mice (n=10 per group).
2. Groups:
   • CT6 D+Q: Dasatinib (5 mg/kg) + Quercetin (50 mg/kg) intraperitoneally at circadian time 6 (lights‑on +6 h) once weekly for 4 weeks.
   • CT18 D+Q: Same dosing at circadian time 18 (opposite phase).
   • Constant D+Q: Same total weekly dose split into daily low‑dose administrations (to match AUC).
   • Vehicle control: Saline + DMSO.
3. Readouts (performed 24 h after final dose):
   • Senescent cell burden via p16^Ink4a^‑GFP flow cytometry in liver, adipose, and kidney.
   • SASP cytokine panel (IL‑6, CCL2) in plasma.
   • Tissue‑specific BCL‑2/BCL‑xL protein levels (Western blot) to confirm phase‑specific trough.
   • Functional assays: grip strength, treadmill endurance, and frailty index.
4. Controls for circadian confounds: Mice housed in 12:12 light‑dark cycles with ad libitum feeding; activity monitored via wheel running to verify entrainment.

Predicted Outcomes

• CT6 D+Q will show ≥40 % greater reduction in p16^+ cells vs CT18 and constant groups (p<0.01).
• Corresponding larger decreases in SASP factors and greater improvements in physical performance.
• Tissue BCL‑2/BCL‑xL levels will be lowest at CT6, confirming mechanistic link.
• If no difference is observed, the hypothesis that senescent cell apoptosis is gated by REV‑ERBα‑driven BCL‑2 oscillations is falsified.

Potential Caveats & Alternatives

• Residual clock arrhythmia in deeply senescent cells could blunt phase‑specific effects; single‑cell RNA‑seq of sorted p16^+ cells will assess clock gene variance.
• Drug pharmacokinetics may vary with circadian metabolism; pilot plasma concentration‑time curves will be obtained to align exposure with target window.
• Compensatory upregulation of MCL‑1 could diminish efficacy; combining with an MCL‑1 inhibitor in a follow‑up arm could test robustness.

Conclusion: Leveraging the intrinsic circadian vulnerability of senescent cells offers a simple, chronotherapeutic strategy to amplify senolytic efficacy without increasing drug dosage, directly testing the notion that restoring temporal coherence is a potent geroprotective intervention.